Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

www.businesswire.com

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has granted approval for Tecartus® (brexucabtagene

  • FDA approved the first CAR-T therapy for Adult B-ALL based on the results of ZUMA-3.